Abcellera Biologics Inc
- Exchange
- US
- Country
- USA
- IPO date
- Dec 11, 2020
- Employees
- 562
- Website
- www.abcellera.com
Composite valuation range · conservative $3.8–$4.3 / fair $5.8–$7.8 / optimistic $9.7–$11. At $6.8, Within the fair intrinsic-value range.
At publication $6.47 (Jul 18, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
History
Coming soonThis section is being filled in — check back soon.
Industry position
Coming soonThis section is being filled in — check back soon.